[go: up one dir, main page]

AR066158A1 - COMPUESTO DE PIRIDAZINA CRISTALINA, UN MÉTODO PARA SU ELABORACIoN Y UNA COMPOSICIoN QUE LO COMPRENDE. - Google Patents

COMPUESTO DE PIRIDAZINA CRISTALINA, UN MÉTODO PARA SU ELABORACIoN Y UNA COMPOSICIoN QUE LO COMPRENDE.

Info

Publication number
AR066158A1
AR066158A1 ARP080102883A ARP080102883A AR066158A1 AR 066158 A1 AR066158 A1 AR 066158A1 AR P080102883 A ARP080102883 A AR P080102883A AR P080102883 A ARP080102883 A AR P080102883A AR 066158 A1 AR066158 A1 AR 066158A1
Authority
AR
Argentina
Prior art keywords
crystalline compound
piridazine
crystaline
elaboration
understands
Prior art date
Application number
ARP080102883A
Other languages
English (en)
Original Assignee
Gilead Sciences Inc
Leuven K U Res & Dev
Puerstinger Gerhard
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39790369&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR066158(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc, Leuven K U Res & Dev, Puerstinger Gerhard filed Critical Gilead Sciences Inc
Publication of AR066158A1 publication Critical patent/AR066158A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proveen un compuesto cristalino de la formula (1) y sus sales y solvatos, para el tratamiento o la profilaxis de infecciones del Virus de la hepatitis C: Se proveen métodos para la elaboracion y la formulacion del compuesto (1) cristalino. Reivindicacion 2: El compuesto cristalino de la reivindicacion 1, que tiene un inicio endotérmico a aproximadamente 235° C en el perfil de calorimetría de barrido diferencial (DSC). Reivindicacion 3: El compuesto cristalino de la reivindicacion 2, que tiene un calor de fusion (DHf) de aproximadamente 81 J/g (42 KJ/mol). Reivindicacion 4: El compuesto cristalino de la reivindicacion 3, que tiene por lo menos un pico aproximado a un ángulo de difraccion 2 theta (°) de aproximadamente 17, medido por difractometría de polvo de rayos X. Reivindicacion 14: Un método para la elaboracion de compuesto cristalino (1): que comprende la cristalizacion de compuesto (1) a partir de solvente de cristalizacion, y el control de la cantidad de agua en el solvente de cristalizacion.
ARP080102883A 2007-07-06 2008-07-03 COMPUESTO DE PIRIDAZINA CRISTALINA, UN MÉTODO PARA SU ELABORACIoN Y UNA COMPOSICIoN QUE LO COMPRENDE. AR066158A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US95859507P 2007-07-06 2007-07-06

Publications (1)

Publication Number Publication Date
AR066158A1 true AR066158A1 (es) 2009-07-29

Family

ID=39790369

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080102883A AR066158A1 (es) 2007-07-06 2008-07-03 COMPUESTO DE PIRIDAZINA CRISTALINA, UN MÉTODO PARA SU ELABORACIoN Y UNA COMPOSICIoN QUE LO COMPRENDE.

Country Status (19)

Country Link
US (2) US8106054B2 (es)
EP (1) EP2170881A1 (es)
JP (2) JP5366944B2 (es)
KR (1) KR101229528B1 (es)
CN (1) CN101778847B (es)
AP (1) AP2593A (es)
AR (1) AR066158A1 (es)
AU (1) AU2008275756B2 (es)
BR (1) BRPI0814801A2 (es)
CA (1) CA2691917C (es)
CO (1) CO6251293A2 (es)
EA (2) EA018173B1 (es)
EC (1) ECSP109919A (es)
IL (1) IL202694A0 (es)
MX (1) MX2009013833A (es)
TW (1) TWI447116B (es)
UA (1) UA99466C2 (es)
WO (1) WO2009009001A1 (es)
ZA (1) ZA201000826B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0215293D0 (en) * 2002-07-03 2002-08-14 Rega Foundation Viral inhibitors
ES2381890T3 (es) 2003-12-22 2012-06-01 K.U.Leuven Research & Development Compuesto de imidazo[4,5-c]piridina y métodos de tratamiento antiviral
PT1841765E (pt) * 2004-12-21 2009-05-14 Gilead Sciences Inc Anticorpos para mcp-1 humano
CA2656415C (en) * 2006-07-07 2012-05-22 Gilead Sciences, Inc. Novel pyridazine compound and use thereof
NZ577208A (en) 2006-12-14 2012-06-29 Gilead Sciences Inc Viral inhibitors
UA99466C2 (en) 2007-07-06 2012-08-27 Гилиад Сайенсиз, Инк. Crystalline pyridazine compound
AU2010333656B2 (en) 2009-12-18 2015-08-27 Boehringer Ingelheim International Gmbh HCV combination therapy
NZ603310A (en) 2010-05-21 2015-01-30 Gilead Sciences Inc Heterocyclic flaviviridae virus inhibitors
US20130273005A1 (en) 2010-12-20 2013-10-17 Gilead Sciences, Inc. Methods for treating hcv
US20120204871A1 (en) * 2011-02-10 2012-08-16 Julio Cesar Vega Stable, non-corrosive formulations for pressurized metered dose inhalers
UA116087C2 (uk) 2011-09-16 2018-02-12 Гіліад Фармассет Елелсі Композиція для лікування вірусу гепатиту c
MY172166A (en) 2013-01-31 2019-11-15 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
EP3939985B1 (en) 2014-12-26 2024-05-08 Emory University Pharmaceutical compositions comprising n4-hydroxycytidine derivatives for the treatment or prevention of influenza or coronavirus infections
ES2995458T3 (en) 2017-12-07 2025-02-10 Univ Emory N4-hydroxycytidine derivative and anti-viral uses related thereto
CN114195812A (zh) * 2021-12-30 2022-03-18 大连联化化学有限公司 一种合成2,4-二三氟甲基苯硼酸的方法

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2191978A (en) 1935-10-10 1940-02-27 Ig Farbenindustrie Ag Quaternary nitrogen compounds and process of preparing them
US2411662A (en) * 1943-05-13 1946-11-26 Geigy Ag J R Imino-di-fatty acid amide
US2548863A (en) 1946-05-29 1951-04-17 Wyeth Corp Substituted glycinamides
US2516674A (en) * 1948-10-29 1950-07-25 Wyeth Corp Substituted glycinamide
US3985891A (en) 1973-02-03 1976-10-12 Boehringer Ingelheim Gmbh 2-Phenyl-imidazo (4,5-b)pyridines and salts thereof
SU813921A1 (ru) 1979-10-26 1986-12-23 Институт физико-органической химии и углехимии АН УССР Стирильные производные имидазо(4,5- @ )пиридиний иодида,обладающие фунгицидной активностью
SU851940A1 (ru) 1980-03-20 1988-04-30 Институт физико-органической химии и углехимии АН УССР Четвертичные соли имидазо @ 4,5-с @ пиридини ,обладающие антимикробной и фунгистатической активностью
SU860463A1 (ru) 1980-04-09 1998-05-27 Институт физико-органической химии и углехимии АН Украинской ССР Производные 4-амино-1,3-диметилимидазо [4,5-с] пиридин-2-она, обладающие акарицидным действием
SU1048742A1 (ru) 1981-03-30 1986-12-23 Институт физико-органической химии и углехимии АН УССР 2,4-Дистирилпроизводные имидазо-(4,5- @ )пиридини ,обладающие бактериостатической и фунгистатической активностью
US4358387A (en) 1981-08-10 1982-11-09 Texaco Inc. Cylinder lubricating oil composition
US5137896A (en) 1981-10-01 1992-08-11 Janssen Pharmaceutica N.V. N-(3-hydroxy-4-piperidinyl)benzamide derivatives
CA1183847A (en) 1981-10-01 1985-03-12 Georges Van Daele N-(3-hydroxy-4-piperidinyl)benzamide derivatives
FR2527608B1 (fr) 1982-05-28 1986-10-10 Sandoz Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments
ZA847926B (en) 1983-10-17 1986-05-28 Lilly Co Eli 3-bicyclicpyridinium-methyl cephalosporins
US4692443A (en) 1983-10-17 1987-09-08 Eli Lilly And Company 3-bicyclicpyridinium-methyl cephalosporins
GB8501542D0 (en) 1985-01-22 1985-02-20 Erba Farmitalia 4 5 6 7-tetrahydro-imidazo(4 5-clpyridine derivatives
GB8530602D0 (en) 1985-12-12 1986-01-22 Fujisawa Pharmaceutical Co Heterocyclic compounds
ATE79620T1 (de) 1986-02-03 1992-09-15 Janssen Pharmaceutica Nv N-heterozyklische-4-piperidinamine enthaltende anti-histaminische zusammensetzungen.
US4804658A (en) 1986-09-15 1989-02-14 G. D. Searle & Co. Imidazopyridine derivatives and pharmaceutical compositions
US5057517A (en) 1987-07-20 1991-10-15 Merck & Co., Inc. Piperazinyl derivatives of purines and isosteres thereof as hypoglycemic agents
IL87149A (en) 1987-07-20 1994-05-30 Merck & Co Inc 6-Piperazinyl derivatives of purine and its 3- and 9-deaza isosteres, their preparation and pharmaceutical compositions containing them
US5302601A (en) 1988-03-14 1994-04-12 G. D. Searle & Co. 5-substituted imidazo[4,5-c]pyridines
US5019581A (en) 1988-03-14 1991-05-28 G. D. Searle & Co. 5-substituted (4,5-c) imidazopyridine compounds which have useful platelet activating factor antagonistic activity
US5227384A (en) 1988-03-14 1993-07-13 G. D. Searle & Co. 5-substituted [4,5-c] imidazopyridines and pharmaceutical use thereof
US4914108A (en) 1988-03-14 1990-04-03 G. D. Searle & Co. 5-substituted(4,5-c)imidazopyridine compounds which have useful platelet activating factor antagonistic activity
US5332744A (en) 1989-05-30 1994-07-26 Merck & Co., Inc. Substituted imidazo-fused 6-membered heterocycles as angiotensin II antagonists
US4988707A (en) 1989-09-13 1991-01-29 G. D. Searle & Co. Pharmacologically active phenylalkanoyl substituted imidazo (4,5-C) pyridines
US4990518A (en) 1989-09-13 1991-02-05 G. D. Searle & Co. Pharmacologically active heteroaryl substituted imidazo (4,5-c) pyridines
FR2663332B1 (fr) 1990-06-15 1997-11-07 Roussel Uclaf Nouvelles cephalosporines comportant en position 3 un radical propenyle substitue par un ammonium quaternaire, leur procede de preparation, leur application comme medicaments, les compositions les renfermant et les nouveaux intermediaires obtenus.
US5011832A (en) 1990-06-26 1991-04-30 Merck & Co., Inc. 2-biphenyl-carbapenem antibacterial agents
JPH04327587A (ja) 1991-04-26 1992-11-17 Asahi Chem Ind Co Ltd ６’−ｃ−アルキル−３−デアザネプラノシンａ誘導体、その製造法およびその用途
DE4122474A1 (de) 1991-07-06 1993-01-07 Basf Ag Fungizide mischung
GB9116056D0 (en) 1991-07-24 1991-09-11 British Bio Technology Compounds
US5587372A (en) 1991-12-12 1996-12-24 Roussel Uclaf Cephalosporins
GB9202792D0 (en) 1992-02-11 1992-03-25 British Bio Technology Compounds
DE4211474A1 (de) 1992-04-06 1993-10-07 Merck Patent Gmbh Imidazopyridine
US20030073159A1 (en) * 1992-05-11 2003-04-17 Human Genome Sciences, Inc. Human inhibitor of apoptosis gene 1
US5208242A (en) 1992-08-26 1993-05-04 G. D. Searle & Co. 5-substituted-4-phenyl-5H-imidazo[4,5-c]pyridine derivatives
DE4230464A1 (de) 1992-09-11 1994-03-17 Merck Patent Gmbh Imidazolderivate
DE4236026A1 (de) 1992-10-24 1994-04-28 Merck Patent Gmbh Imidazopyridine
JP3115455B2 (ja) 1992-12-18 2000-12-04 明治製菓株式会社 新規セファロスポリン誘導体
US5374638A (en) 1993-03-19 1994-12-20 Merck & Co., Inc. Six membered ring fused imidazoles substituted with phenoxyphenylacetic acid derivatives used to treat asthma
DE4309969A1 (de) 1993-03-26 1994-09-29 Bayer Ag Substituierte heteroanellierte Imidazole
DE4318813A1 (de) 1993-06-07 1994-12-08 Merck Patent Gmbh Imidazopyridine
DE4324580A1 (de) 1993-07-22 1995-01-26 Thomae Gmbh Dr K Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US5486525A (en) 1993-12-16 1996-01-23 Abbott Laboratories Platelet activating factor antagonists: imidazopyridine indoles
US5563143A (en) 1994-09-21 1996-10-08 Pfizer Inc. Catechol diether compounds as inhibitors of TNF release
US6506876B1 (en) 1994-10-11 2003-01-14 G.D. Searle & Co. LTA4 hydrolase inhibitor pharmaceutical compositions and methods of use
US5585492A (en) 1994-10-11 1996-12-17 G. D. Searle & Co. LTA4 Hydrolase inhibitors
US6080870A (en) 1996-04-03 2000-06-27 Merck & Co., Inc. Biaryl substituted imidazole compounds useful as farnesyl-protein transferase inhibitors
US5874452A (en) 1996-04-03 1999-02-23 Merck & Co., Inc. Biheteroaryl inhibitors of farnesyl-protein transferase
US5854265A (en) 1996-04-03 1998-12-29 Merck & Co., Inc. Biheteroaryl inhibitors of farnesyl-protein transferase
US5872136A (en) 1996-04-03 1999-02-16 Merck & Co., Inc. Arylheteroaryl inhibitors of farnesyl-protein transferase
US5883105A (en) 1996-04-03 1999-03-16 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5939557A (en) 1996-04-03 1999-08-17 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5859035A (en) 1996-04-03 1999-01-12 Merck & Co., Inc. Arylheteroaryl inhibitors of farnesyl-protein transferase
US5880140A (en) 1996-04-03 1999-03-09 Merck & Co., Inc. Biheteroaryl inhibitors of farnesyl-protein transferase
US6063930A (en) 1996-04-03 2000-05-16 Merck & Co., Inc. Substituted imidazole compounds useful as farnesyl-protein transferase inhibitors
JP4375901B2 (ja) 1997-11-28 2009-12-02 大日本住友製薬株式会社 新規な複素環化合物
DE19845153A1 (de) 1998-10-01 2000-04-06 Merck Patent Gmbh Imidazo[4,5]-pyridin-4-on-derivate
DE19900471A1 (de) 1999-01-08 2000-07-13 Merck Patent Gmbh Imidazo[4,5c]-pyridin-4-on-derivate
JP4055363B2 (ja) 1999-01-08 2008-03-05 チッソ株式会社 ボラン誘導体および有機電界発光素子
US6627651B1 (en) 1999-05-07 2003-09-30 Takeda Chemical Industries, Ltd. Cyclic compounds and uses thereof
US6844367B1 (en) 1999-09-17 2005-01-18 Millennium Pharmaceuticals, Inc. Benzamides and related inhibitors of factor Xa
US6770666B2 (en) 1999-12-27 2004-08-03 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs
WO2001047883A1 (fr) 1999-12-27 2001-07-05 Japan Tobacco Inc. Composes a cycles accoles et leur utilisation comme medicaments
US6376515B2 (en) 2000-02-29 2002-04-23 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor Xa
EP1132381A1 (en) 2000-03-08 2001-09-12 Cermol S.A. Ester derivatives of dimethylpropionic acid and pharmaceutical compositions containing them
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
EP1386923B1 (en) 2001-04-17 2008-08-13 Dainippon Sumitomo Pharma Co., Ltd. Novel adenine derivatives
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
US20030073836A1 (en) * 2001-07-05 2003-04-17 Boehringer Ingelheim Pharma Kg Heteroarylcarboxylic acid amides, the preparation thereof and their use as pharmaceutical compositions
US7294457B2 (en) 2001-08-07 2007-11-13 Boehringer Ingelheim (Canada) Ltd. Direct binding assay for identifying inhibitors of HCV polymerase
DE10140246A1 (de) 2001-08-09 2003-03-06 Forsch Pigmente Und Lacke E V Verfahren zur Behandlung von Oberflächen von Substraten
US20030134853A1 (en) 2001-09-26 2003-07-17 Priestley Eldon Scott Compounds useful for treating hepatitis C virus
JP2005525309A (ja) 2002-01-10 2005-08-25 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 医薬品としての使用のためのＭＴＰインヒビター又はａｐｏＢ分泌インヒビターとフィブレートの組み合わせ
GB0215293D0 (en) 2002-07-03 2002-08-14 Rega Foundation Viral inhibitors
KR101150449B1 (ko) 2002-08-21 2012-06-01 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 8-［3-아미노-피페리딘-1-일］-크산틴, 이의 제조방법 및 이를 포함하는 약제학적 조성물
CN1678306A (zh) 2002-08-29 2005-10-05 贝林格尔·英格海姆药物公司 在炎性、变应性和增生性疾病中用作糖皮质激素模拟物的3－(磺酰氨基乙基)－吲哚衍生物
CN1744899A (zh) 2002-12-13 2006-03-08 史密丝克莱恩比彻姆公司 作为ccr5拮抗剂的哌啶衍生物
US7223785B2 (en) * 2003-01-22 2007-05-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US7098231B2 (en) * 2003-01-22 2006-08-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
EP1590334B1 (en) 2003-01-30 2009-08-19 Boehringer Ingelheim Pharmaceuticals Inc. 2,4-diaminopyrimidine derivatives useful as inhibitors of pkc-theta
US7566707B2 (en) * 2003-06-18 2009-07-28 Boehringer Ingelheim International Gmbh Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions
AU2004291262C1 (en) * 2003-11-05 2011-08-11 F. Hoffmann-La Roche Ag Phenyl derivatives as PPAR agonists
ES2381890T3 (es) * 2003-12-22 2012-06-01 K.U.Leuven Research & Development Compuesto de imidazo[4,5-c]piridina y métodos de tratamiento antiviral
EP1781658A1 (en) 2004-07-27 2007-05-09 Gilead Sciences, Inc. Imidazoý4,5-d¨pyrimidines, their uses and methods of preparation
CN101018843B (zh) 2004-09-13 2011-05-11 西巴特殊化学品控股有限公司 烷基氨基乙酰胺润滑添加剂
PT1841765E (pt) 2004-12-21 2009-05-14 Gilead Sciences Inc Anticorpos para mcp-1 humano
WO2007063744A1 (ja) 2005-11-30 2007-06-07 Fujifilm Corporation 平版刷版の後露光方法、後露光装置、露光装置、露光用器具、現像方法、及び現像装置
CA2656415C (en) 2006-07-07 2012-05-22 Gilead Sciences, Inc. Novel pyridazine compound and use thereof
UA99466C2 (en) 2007-07-06 2012-08-27 Гилиад Сайенсиз, Инк. Crystalline pyridazine compound

Also Published As

Publication number Publication date
JP5366944B2 (ja) 2013-12-11
WO2009009001A1 (en) 2009-01-15
JP2010532757A (ja) 2010-10-14
TWI447116B (zh) 2014-08-01
BRPI0814801A2 (pt) 2017-03-28
IL202694A0 (en) 2010-06-30
CA2691917A1 (en) 2009-01-15
WO2009009001A9 (en) 2010-11-11
MX2009013833A (es) 2010-03-10
EA200971080A1 (ru) 2010-08-30
UA99466C2 (en) 2012-08-27
CO6251293A2 (es) 2011-02-21
AP2009005078A0 (en) 2009-12-31
CN101778847A (zh) 2010-07-14
EA018173B1 (ru) 2013-06-28
US20120108601A1 (en) 2012-05-03
AU2008275756A1 (en) 2009-01-15
JP2013216695A (ja) 2013-10-24
CA2691917C (en) 2013-12-03
US8569488B2 (en) 2013-10-29
EP2170881A1 (en) 2010-04-07
KR101229528B1 (ko) 2013-02-04
AP2593A (en) 2013-02-07
TW200918531A (en) 2009-05-01
AU2008275756B2 (en) 2012-01-19
US20090036460A1 (en) 2009-02-05
EA201270275A1 (ru) 2012-09-28
ECSP109919A (es) 2010-04-30
US8106054B2 (en) 2012-01-31
KR20100044201A (ko) 2010-04-29
CN101778847B (zh) 2013-07-24
ZA201000826B (en) 2010-11-24

Similar Documents

Publication Publication Date Title
AR066158A1 (es) COMPUESTO DE PIRIDAZINA CRISTALINA, UN MÉTODO PARA SU ELABORACIoN Y UNA COMPOSICIoN QUE LO COMPRENDE.
AR122395A2 (es) Formas cristalinas de 5-cloro-n2-(2-isopropoxi-5-metil-4-piperidin-4-il-fenil)-n4-[2-(propan-2-sulfonil)-fenil]-pirimidin-2,4-diamina
HRP20210388T4 (hr) Kristalni polimorf slobodne baze od 2-hidroksi-6-((2-(1-izopropil-1h-pirazol-5-il)piridin-3-il)metoksi)benzaldehida
ES2613716T3 (es) Formas cristalinas de un derivado de purina
AR079257A1 (es) Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas
EA200802119A1 (ru) Новая кристаллическая форма vi агомелатина, способ его получения и фармацевтические композиции, которые ее содержат
MX2021007251A (es) Formas polimorficas novedosas de un inhibidor de tgf?.
CY1115514T1 (el) Αντι-μολυσματικες πυραμιδινες και χρησεις αυτων
IL296199B2 (en) Salt form of a human hi stone methyltransf erase ezh2 inhibitor
AR073298A1 (es) Formas cristalinas del 2-tiazolil-4-quinolil-oxi amidas, composiciones farmaceuticas que las contienen y uso de las mismas en el tratamiento de la infeccion por hcv.
CL2008003431A1 (es) Compuestos derivados de nucleosidos 2',4' sustituidos; proceso de preparacion de dichos compuestos; composicion farmaceutica que los comprende; su metodo de preparacion; y su uso para el tratamiento y/o la prevencion de cualquier condicion resultante de una infeccion por vhb, vhc o vih.
PE20060284A1 (es) Formas polimorficas de 3-(4-amino-1-oxo-1,3-dihidro-soindol-2-il)-piperidin-2,6-diona
AR073769A1 (es) Inhibidores de la integrasa del vih derivados de azepina y oxazepinas condensadas, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de infecciones por vih.
CO2023006513A2 (es) Forma cristalina iii del compuesto agonista de receptor de melanocortina y método de preparación para la misma
BRPI0600795A (pt) forma betad-cristalina de cloridrato de ivabradina, um processo para preparação do mesmo e composições farmacêuticas contendo o mesmo
HRP20192132T1 (hr) Antagonist nk-1/nk-3 receptora za liječenje valunga
CO2023006515A2 (es) Forma cristalina i del compuesto agonista de receptor de melanocortina y método de preparación para la misma
EA200601273A1 (ru) Новая кристаллическая форма v агомелатина, способ её получения и фармацевтические композиции, которые её содержат
AR080490A1 (es) FORMAS CRISTALINAS DE UN INHIBIDOR DE ELASTASA NEUTROFILA, COMPOSICIoN FARMACEUTICA QUE LAS COMPRENDE Y SU USO EN LA FABRICACION DE UN MEDICAMENTO PARA EL TRATAMIENTO DE LA DEFICIENCIA DE ALFA-1-ANTITRIPSINA
EA200601271A1 (ru) Новая кристаллическая форма iv агомелатина, способ её получения и фармацевтические композиции, которые её содержат
BRPI0603074A (pt) forma cristalina iii de agomelatina, um processo para sua preparação e composições farmacêuticas contendo-a
JP2016534961A5 (es)
UA89905C2 (ru) α КРИСТАЛЛИЧЕСКАЯ ФОРМА АРГИНИНОВОЙ СОЛИ ПЕРИНДОПРИЛА, СПОСОБ ЕЕ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, КОТОРАЯ ЕЕ СОДЕРЖИТ
MX2019012967A (es) Cristal de base libre de derivados benzofurano y metodo de preparacion.
PH12012500992A1 (en) Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use

Legal Events

Date Code Title Description
FB Suspension of granting procedure